The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we
Evaluation of the immunocompetence of patients with transitional cell carcinoma of the bladder
β Scribed by Adolphs, H.-D. ;Steffens, L.
- Publisher
- Springer
- Year
- 1977
- Tongue
- English
- Weight
- 411 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
β¦ Synopsis
The cellular immunocompetence was examined by means of the quantitative DNCB hypersensitivity reaction in 152 patients with transitional cell carcinomas of the bladder of Broders grades 1-4. Against a control group of 367 normal controls of both sexes, 85 patients with transitional cell carcinomas of grades 1 and 2 showed a normal DNCB reactivity, irrespective of the frequency of tumour recurrence. In 9 patients of this group, an increase of malignancy from grade 2 to grade 3 was observed; the simultaneous deterioration of immunocompetence, however, was not statistically significant. On the other hand, with transitional cell carcinomas of grades 3 and 4, significant impairment of immunocompetence correlating with the tumour stage was noted.
π SIMILAR VOLUMES
## Abstract This report is the first described case of transitional cell carcinoma of the bladder metastatic to the female breast. The patient is a 42βyearβold woman who underwent radical cystectomy three months prior to presentation with two asymptomatic right breast masses as the first evidence o